(Bone marrow-derived mesenchymal stromal cells(The University of Queensland)) - 在研适应症：同种异体移植排斥反应_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名

bone marrow-derived mesenchymal stromal cells(The University of Queensland)、Bone-marrow derived MSCs(The University of Queensland)

靶点-

作用机制

细胞替代物

治疗领域

免疫系统疾病

在研适应症

同种异体移植排斥反应

非在研适应症

扩张型心肌病冠心病抑郁症+ [14]

原研机构

The University of Queensland

在研机构

The University of Queensland

非在研机构

Hospital General Universitario Gregorio Marañón

Leids Universitair Medisch Centrum

Emory University

+ [1]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

10

项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的临床试验

NCT05559801 / Not yet recruiting临床1/2期IIT

A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)

This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.

开始日期2024-04-01

申办/合作机构

Emory University

NCT05288725 / Not yet recruiting临床1/2期IIT

A Study to Evaluate the Safety, and Efficacy of Minimally Manipulated Autologous Bone Marrow Aspirate to Treat Knee Osteoarthritis in Patients

The study is a multicentered, randomized, double-blinded, placebo-controlled study conducted on the unilateral knee of 120 patients. The study compares the effectiveness of an injection of a mesenchymal stem cell preparation from autologous bone marrow aspirate (BMA) to a corticosteroid control for knee osteoarthritis. WOMAC, VAS pain scores, and MRI will be used for assessment. The study will be conducted at 3 sites in the United States.

开始日期2022-08-01

申办/合作机构-

ACTRN12620000840987 / Recruiting临床1期IIT

Phase I trial on safety and tolerability of bone-marrow derived mesenchymal stromal cells (MSC) for deteriorating COVID-19 pneumonia

开始日期2020-05-05

申办/合作机构-

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的临床结果

登录后查看更多信息

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的转化医学

登录后查看更多信息

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的专利（医药）

登录后查看更多信息

4

项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的文献（医药）

2021-04-01·ERJ Open Research

Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial

Article

作者: Cordovilla, Rosa ; Villaron, Eva ; Nuñez-Córdoba, Jorge ; González-Ruiz, José María ; Andreu, Enrique ; Barrueco, Miguel ; Zulueta, Javier J ; Prósper, Felipe ; De-Torres, Juan ; Alcaide, Ana B ; Pueyo, Jesús ; Campo, Arantza ; Sanchez-Guijo, Fermín ; Ocón, María M

Rationale:

Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.

Objectives:

To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.

Methods:

A phase I multicentre clinical trial (ClinicalTrials.gov NCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106 and 100×106 cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.

Results:

21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.

Conclusions:

The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.

2021-01-01·Journal of Biological Chemistry

Withdrawal: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis

Article

作者: Wang, Tao ; Wang, Chunmei ; Chen, Taoyong ; Xia, Dajing ; Chen, Guoyou ; Wan, Tao ; Li, Nan ; Cao, Xuetao

2020-06-01·Journal of Biological Chemistry

Expression of Concern: Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis.

Article

100 项与 Bone marrow-derived mesenchymal stromal cells(The University of Queensland) 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
同种异体移植排斥反应	临床2期	澳大利亚更多	The University of Queensland 更多
扩张型心肌病	无进展	西班牙更多	Hospital General Universitario Gregorio Marañón 更多
疼痛	无进展	美国更多	Emory University 更多
抑郁症	无进展	美国更多	Emory University 更多
肾移植排斥反应	无进展	荷兰更多	Leids Universitair Medisch Centrum 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03818737 (CTgov)	临床3期	膝关节炎	475	Bone Marrow Derived MSCs (Bone Marrow Derived MSCs)	壓糧鏇廠鑰繭鬱艱網鹽(艱鏇艱範構艱選廠獵襯) = 夢鹹觸衊衊製築襯艱獵遞遞醖憲選膚醖製鬱餘 (鬱築網範窪膚艱製範蓋, 鬱鏇醖夢淵構窪範壓顧 ~ 積蓋窪築衊淵鑰獵選簾) 更多	-	2023-07-27
				Adipose-derived MSCs (Adipose-derived MSCs)	壓糧鏇廠鑰繭鬱艱網鹽(艱鏇艱範構艱選廠獵襯) = 繭遞鑰蓋網膚壓餘獵廠遞遞醖憲選膚醖製鬱餘 (鬱築網範窪膚艱製範蓋, 築簾觸觸積鹹壓鏇繭鏇 ~ 範簾鏇顧壓鑰鬱製糧構) 更多
HOVON-113 (EHA2022) 人工标引	临床3期	类固醇难治性移植物抗宿主病	41	Mesenchymal stromal cell	鏇網襯願遞築衊願網觸(鬱襯衊齋簾蓋顧鹽繭範) = 鏇構鏇觸願窪憲窪衊獵夢糧簾願構蓋衊選製鑰 (衊鬱鹹顧繭窪餘遞淵鹹 ) 更多	不佳	2022-05-12
				placebo	鏇網襯願遞築衊願網觸(鬱襯衊齋簾蓋顧鹽繭範) = 範鏇鏇簾鏇廠製齋衊窪夢糧簾願構蓋衊選製鑰 (衊鬱鹹顧繭窪餘遞淵鹹 ) 更多